Home | Welcome to Contract Pharma   
Last Updated Wednesday, August 27 2014
Print

Search Results for 'biopharma'

Search For:
Refine by Dates:
From: To:
Past 7 Days        Past 30 Days
Refine By Content:

Search Results:

Published June 14, 2011
Array BioPharma will restructure in an effort to extend its financial resources to focus on the development of key clinical programs: ARRY-520, a KSP inhibitor for multiple myeloma, ARRY-614, a p38 / Tie-2 inhibitor for myelodysplastic syndrome, and MEK162, a MEK inhibitor for cancer in co-development with Novartis. Read More »
Biopharmaceutical Outsourcing For 2011
By Eric S. Langer, BioPlan Associates
Published June 6, 2011
New study defines trends, growth Read More »
Published March 28, 2011
Peter S. Linsley, Ph.D., has been appointed chief scientific officer of AVI BioPharma, Inc., effective May 1, 2011. Read More »
Published January 21, 2010
AlphaRx Inc.’s licensee, Gaia BioPharma Ltd., has signed an agreement with a CMO to manufacture GAI-122 for use in Phase I and II trials. Read More »
Published April 27, 2009
Novozymes Biopharma has begun construction of a new cGMP facility at its existing site in Tianjin, China, enabling the company to produce Bacillus-based Hyaluronic Acid (bHA), HyaCare, for the bio-medical and pharmaceutical industries. Read More »
Published August 20, 2008
Bristol-Myers Squibb and PDL BioPharma, Inc. entered an agreement for the global development and commercialization of PDL’s anti-CS1 antibody, elotuzumab, currently in Phase I development for multiple myeloma.     Elotuzumab o… Read More »
Published December 13, 2006
Holmes Biopharma, Inc. has signed a letter of intent to purchase an existing pharmaceutical development, clinical manufacture, biotechnology, and analytical laboratory business located in the eastern U.S. The name and terms of the acquisition will be… Read More »
Published July 7, 2006
PDL BioPharma, Inc. plans to move its corporate headquarters from Fremont to Redwood City, CA during the third quarter of 2007. PDL has signed long-term leases for two existing buildings that total approximately 450,000 sq.-ft. The new headquarters w… Read More »
Published April 17, 2006
Sentry Logistic Solutions launched its services and the opening of its $8 million, 53,000-sq.-ft. facility designed for cold chain logistics, storage and packing of bulk pharmaceutical and biotechnology components and finished products. "Se… Read More »
Published March 8, 2006
PDL BioPharma, Inc. has named Andrew Guggenhime senior vice president and chief financial officer. Mr. Guggenhime will join the company's senior management team reporting directly to chief executive officer Mark McDade, and will be responsible for al… Read More »
Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On